Avtal
Avtal
Sidan uppdaterad 2020-06-24
Regionerna samverkar kring att nå avtalsrelationer med läkemedelsföretag för både recept- och rekvisitionsläkemedel. Avtalen kan ofta utgöra en förutsättning för en NT-rådsrekommendation men kan även baseras på andra skäl för regionsamverkan. Det gäller till exempel vissa receptläkemedel där samverkan med TLV och läkemedelsföretag (så kallad trepartsöverläggning) kan leda fram till avtal som samtliga regioner tecknar. Regionernas arbete med avtal stöds och koordineras av de gemensamma funktionerna Marknad och Förhandling.
Sammanställningen nedan omfattar de avtal som tagits fram gemensamt inom ramen för regionernas samverkansmodell för läkemedel och innehåller endast aktuella, giltiga avtal.
Klicka på kolumnrubriken för att sortera
ATC-kod | Substans | Läkemedel | Företag (avtalspart) | Recept/rekvisition | Avtalsstart | Avtalsslut | Förl. option tom. |
|---|---|---|---|---|---|---|---|
A16AB10 | velagluceras alfa | VPRIV | Shire Sweden AB | rekvisition | 2019-04-01 | 2021-03-31 | 2023-03-31 |
A16AX07 | sapropterin | Kuvan | BioMarin International | recept | 2017-11-01 | 2020-10-31 | . |
A16AX15 | telotristatetyl | Xermelo | Ipsen | recept | 2018-06-01 | 2020-05-31 | 2021-05-31 |
B02BD02 | koagulations-faktor VIII | Advate | Shire Sweden AB | recept | 2020-06-01 | 2022-05-31 | 2023-05-31 |
B02BD02 | koagulations-faktor VIII | Adynovi | Shire Sweden AB | recept | 2020-06-01 | 2022-05-31 | 2023-05-31 |
B02BD02 | koagulations-faktor VIII | Afstyla | CSL Behring AB | recept | 2020-06-01 | 2022-05-31 | 2023-05-31 |
B02BD02 | koagulations-faktor VIII | Elocta | Swedish Orphan Biovitrum | recept | 2020-06-01 | 2022-05-31 | 2023-05-31 |
B02BD02 | koagulations-faktor VIII | Esperoct | Novo Nordisk AB | recept | 2020-06-01 | 2022-05-31 | 2023-05-31 |
B02BD02 | koagulations-faktor VIII | Jivi | Bayer AB | recept | 2020-06-01 | 2022-05-31 | 2023-05-31 |
B02BD02 | koagulations-faktor VIII | Kovaltry | Bayer AB | recept | 2020-06-01 | 2022-05-31 | 2023-05-31 |
B02BD02 | koagulations-faktor VIII | NovoEight | Novo Nordisk AB | recept | 2020-06-01 | 2022-05-31 | 2023-05-31 |
B02BD02 | koagulations-faktor VIII | Nuwiq | Octapharma Nordic AB | recept | 2020-06-01 | 2022-05-31 | 2023-05-31 |
B02BD02 | koagulations-faktor VIII | Refacto AF | Pfizer Innovations | recept | 2020-06-01 | 2022-05-31 | 2023-05-31 |
B02BD02 | koagulations-faktor VIII | Octanate | Octapharma Nordic AB | recept | 2020-06-01 | 2022-05-31 | 2023-05-31 |
B02BD02 | koagulations-faktor VIII | Octanate LV | Octapharma Nordic AB | recept | 2020-06-01 | 2022-05-31 | 2023-05-31 |
C03XA01 | tolvaptan | Jinarc | Otsuka Pharma Scandinavia | rekvisition | 2017-04-01 | 2021-03-31 | . |
C10AX13 | evolocumab | Repatha | Amgen AB | recept | 2019-01-01 | 2020-12-31 | 2021-12-31 |
C10AX14 | alirocumab | Praluent | Sanofi AB | recept | 2019-01-01 | 2020-12-31 | 2021-12-31 |
D11AH05 | dupilumab | Dupixent | Sanofi AB | recept | 2020-01-01 | 2021-12-31 | 2022-12-31 |
J05AP08 | sofosbuvir | Sovaldi | Gilead Sciences Sweden AB | recept | 2018-01-01 | 2020-12-31 | . |
J05AP51 | ledipasvir + sofosbuvir | Harvoni | Gilead Sciences Sweden AB | recept | 2018-01-01 | 2020-12-31 | . |
J05AP54 | elbasvir + grazoprevir | Zepatier | MSD | recept | 2018-01-01 | 2020-12-31 | . |
J05AP55 | sofosbuvir + velpatasvir | Epclusa | Gilead Sciences Sweden AB | recept | 2018-01-01 | 2020-12-31 | . |
J05AP56 | sofosbuvir + velpatasvir + voxilaprevir | Vosevi | Gilead Sciences Sweden AB | recept | 2018-01-01 | 2020-12-31 | . |
L01CD01 | nab-paklitaxel | Pazenir | Teva Sweden AB | rekvisition | 2020-04-01 | 2021-03-31 | 2022-03-31 |
L01CD01 | nab-paklitaxel | Abraxane | Celgene AB | rekvisition | 2020-04-01 | 2020-03-31 | 2022-03-31 |
L01CD04 | cabazitaxel | Jevtana | Sanofi AB | rekvisition | 2017-07-01 | 2021-06-30 | . |
L01XX70 | axikabtagen-ciloleucel | Yescarta | Gilead Sciences Sweden AB | rekvisition | från avtalstecknande | 2020-11-30 | 2021-05-31 |
L01XX71 | tisagenlekleucel | Kymriah | Novartis Sverige AB | rekvisition | 2019-05-15 | 2020-11-30 | 2021-05-31 |
L01XC11 | ipilimumab | Yervoy | Bristol-Myers Squibb AB | rekvisition | 2020-01-01 | 2020-12-31 | 2022-12-31 |
L01XC13 | pertuzumab | Perjeta | Roche AB | rekvisition | 2019-01-01 | 2020-12-31 | 2022-12-31 |
L01XC14 | trastuzumab- emtansin | Kadcyla | Roche AB | rekvisition | 2020-01-01 | 2021-12-31 | 2023-12-31 |
L01XC17 | nivolumab | Opdivo | Bristol-Myers Squibb AB | rekvisition | 2017-04-01 | 2020-12-31 | 2021-03-31 |
L01XC18 | pembrolizumab | Keytruda | Merck Sharp & Dohme (Sweden) AB | rekvisition | 2017-04-01 | 2020-12-31 | . |
L01XC21 | ramucirumab | Cyramza | Lilly | rekvisition | 2017-06-01 | 2020-11-30 | . |
L01XC24 | daratumumab | Darzalex | Janssen Cilag | rekvisition | 2018-05-01 | 2020-06-30 | . |
L01XC24 | daratumumab | Darzalex | Janssen Cilag | rekvisition | 2020-07-01 | 2022-06-30 | 2024-06-30 |
L01XC28 | durvalumab | Imfinzi | AstraZeneca | rekvisition | 2018-11-01 | 2020-12-31 | 2021-03-31 |
L01XC31 | avelumab | Bavencio | Merck | rekvisition | 2018-03-22 | 2020-12-31 | 2021-03-31 |
L01XC32 | atezolizumab | Tecentriq | Roche AB | rekvisition | 2017-12-01 | 2020-12-31 | 2021-03-31 |
L01XE25 | trametinib | Mekinist | Novartis Sverige AB | recept | 2020-01-01 | 2021-12-31 | 2022-12-31 |
L01XE26 | cabozantinib | Cabometyx | Ipsen | recept | 2018-04-01 | 2021-03-31 | . |
L01XE33 | palbociklib | Ibrance | Pfizer Innovations | recept | 2017-07-01 | 2021-06-30 | . |
L01XE35 | osimertinib | Tagrisso | AstraZeneca | recept | 2017-10-01 | 2020-09-30 | . |
L01XE41 | binimetinib | Mektovi | Pierre Fabre | recept | 2020-01-01 | 2021-12-31 | 2022-12-31 |
L01XE42 | ribociklib | Kisqali | Novartis Sverige AB | recept | 2018-02-01 | 2020-06-30 | . |
L01XE50 | abemaciklib | Verzenios | Eli Lilly Sweden AB | recept | 2019-07-01 | 2021-06-30 | . |
L01XX45 | karfilzomib | Kyprolis | Amgen AB | rekvisition | 2020-03-01 | 2021-03-31 | 2022-03-31 |
L01XX50 | ixazomib | Ninlaro | Takeda Pharma | recept | 2018-06-01 | 2021-05-31 | . |
L01XX52 | venetoklax | Venclyxto | AbbVie AB | recept | 2018-05-01 | 2021-04-30 | . |
L01XX54 | niraparib | Zejula | GlaxoSmithKline | recept | 2019-12-01 | 2021-05-31 | 2022-12-31 |
L02BB04 | enzalutamid | Xtandi | Astellas Pharma AB | recept | 2020-06-01 | 2022-05-31 | 2023-05-31 |
L02BX03 | abirateron | Zytiga | Janssen-Cilag AB | recept | 2020-06-01 | 2022-05-31 | 2023-05-31 |
L04AA29 | tofacitinib | Xeljanz | Pfizer Innovations | recept | 2017-10-01 | 2020-09-30 | . |
L04AA37 | baricitinib | Olumiant | Lilly | recept | 2017-10-01 | 2020-09-30 | . |
L04AB01 | etanercept | Benepali | Biogen Sweden AB | recept | 2017-10-01 | 2020-09-30 | . |
L04AB01 | etanercept | Enbrel | Pfizer Innovations | recept | 2017-10-01 | 2020-09-30 | . |
L04AB01 | etanercept | Erelzi | Sandoz AS | recept | 2017-10-01 | 2020-09-30 | . |
L04AB04 | adalimumab | Humira | Abbvie | recept | 2017-10-01 | 2020-09-30 | . |
L04AB04 | adalimumab | Amgevita | Amgen AB | recept | 2018-12-01 | 2020-09-30 | . |
L04AB04 | adalimumab | Hyrimoz | Sandoz AS | recept | 2018-12-01 | 2020-09-30 | . |
L04AB04 | Idacio | Idacio | Fresenius Kabi | recept | 2019-10-01 | 2020-09-30 | . |
L04AB04 | adalimumab | Imraldi | Biogen Sweden AB | recept | 2018-12-01 | 2019-09-30 | 2020-09-30 |
L04AX04 | lenalidomid | Revlimid | Celgene | recept | 2019-03-01 | 2021-02-28 | 2022-02-28 |
L04AX06 | pomalidomid | Imnovid | Celgene | recept | 2019-06-01 | 2021-05-31 | 2022-05-31 |
M05BX05 | burosumab | Crysvita | Kyowa Kirin | rekvisition | 2019-06-01 | 2021-12-31 | 2022-05-31 |
M09AX03 | ataluren | Translarna | PTC Therapeutics | recept | 2019-05-01 | 2021-04-30 | 2022-04-30 |
M09AX07 | nusinersen | Spinraza | Biogen | rekvisition | 2017-12-01 | 2020-11-30 | 2021-11-30 |
N02CX07 | erenumab | Aimovig | Novartis Sverige AB | recept | 2019-01-01 | 2020-12-31 | 2021-12-31 |
N07 | inotersen | Tegsedi | Akcea Therapeutics Ireland Ltd | rekvisition | 2019-11-01 | 2021-10-31 | 2022-10-31 |
N07XX08 | tafamidis | Vyndaqel | Pfizer AB | rekvisition | 2020-01-01 | 2021-12-31 | 2022-12-31 |
N07XX12 | patisiran | Onpattro | Alnylam Sweden | rekvisition | 2019-11-01 | 2021-10-31 | 2022-10-31 |
R03DX08 | reslizumab | Cinqaero | Teva | rekvisition | 2018-09-01 | 2020-08-31 | 2022-08-31 |
R03DX10 | mepolizumab | Nucala | GlaxoSmithKline | rekvisition | 2018-09-01 | 2020-08-31 | 2022-08-31 |
R03DX10 | benralizumab | Fasenra | AstraZeneca | rekvisition | 2018-09-01 | 2020-08-31 | 2022-08-31 |
R07AX30 | ivakaftor/ lumakaftor | Orkambi | Vertex Pharmaceuticals Europé | recept | 2018-07-01 | 2022-06-30 | 2028-06-30 |
V03AB37 | idarucizumab | Praxbind | Boehringer Ingelheim AB | rekvisition | 2019-01-01 | 2020-12-31 | 2021-12-31 |
V10XX04 | Iutetium(Lu-177) oxodotreotid | Lutathera | SAM Nordic | rekvisition | 2018-09-01 | 2020-08-31 | 2022-08-31 |